Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial

BACKGROUND: We assessed the safety, immunogenicity and antibody persistence of two- and three-dose schedules of the novel bivalent HPV16/18 vaccine (HPV-2, Walrinvax) in the per-protocol target population of initially seronegative 9–14 year-old girls, including a non-inferiority comparison with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Shi, Li-Wei, Li, Ke, Huang, Li-Rong, Li, Jian-Biao, Dong, Yu-Lian, Li, Wei, Ji, Min, Yang, Qing, Zhou, Ling-Yun, Yuan, Lin, Yan, Xue-Mei, Chen, Jing-Jing, Jiang, Zhi-Wei, Qi, Yang-Yang, Li, Rong-Cheng, Li, Yan-Ping, Xia, Jie-Lai, Yu, Bang-Wei, Mo, Zhao-Jun, Li, Chang-Gui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680975/
http://dx.doi.org/10.1016/j.vaccine.2023.10.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680975/
http://dx.doi.org/10.1016/j.vaccine.2023.10.041

Ejemplares similares